Biotech Values

[RockRat]

There is some foundation for CRP being a bad actor rather than just a marker of bad acting . . .

http://www.medscape.com/viewarticle/542749

Considering this is from 2006, one wonders what happened to the molecule. Pentraxin Therapeutics has made much hype of the portfolio, but not much has gone anywhere. In the case of their CRP inhibitor, they suggested in '06 that trials might begin in a couple of year with adequate support . . .

More recently this:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2662775/

That said, I hope they get proof of concept in less expensive indications first (which does seem to be the strategy) and then partner it or shelve it.

Regards, RockRat